Tuberculosis
Conditions
Interventions
Case series:None
Sponsors
The Third People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The age range of the participants in this study was 18 to 65 years old. 2. This study included patients who had a confirmed diagnosis of pulmonary tuberculosis or underwent pulmonary resection at our hospital or affiliated units. The diagnostic criteria for clinical diagnosis were as follows: A) Patients with positive sputum before surgery, diagnosed with pulmonary tuberculosis based on chest X-ray and CT examination, and confirmed by postoperative pathological examination; B) Patients with negative sputum before surgery, diagnosed with pulmonary tuberculosis based on chest X-ray and CT examination, and confirmed by postoperative pathological examination were also included in this study. 3. All patients included in this study had complete clinicopathological data.
Exclusion criteria
Exclusion criteria: 1. Do not participate in this study. 2. Human immunodeficiency virus positive status. 3. Complicated with other conditions that compromise the immune system. 4. Long-term use of systemic steroids or immunosuppressive medications. 5. If the preoperative sputum test was negative, but chest X-ray and CT scan indicated pulmonary tuberculosis, the pathological diagnosis did not confirm tuberculosis. 6. Related pulmonary and systemic diseases that may impact lung injury and the immune microenvironment include: a) Autoimmune diseases: autoimmune response against one's own tissues resulting in lung damage and alterations in the immune microenvironment (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma). b) Connective tissue diseases: disorders affecting connective tissue directly or indirectly impacting lungs (e.g., rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease). c) Inflammatory granulomatous diseases: inflammation leading to granuloma formation affecting both lungs and the immune microenvironment (e.g., polyarteritis granularis, polyarteritis nodosa). d) Immune-related lung infections: certain conditions increasing risk of lung infections causing damage to lungs (e.g., individuals using immunosuppressants more susceptible to bacterial, fungal or viral infections). e) Other systemic disease-associated lung damage: some diseases causing lung damage or impacting immune microenvironment such as diabetes mellitus, hypertension and cardiovascular disease increasing risk of lung injury.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune microenvironment;TCR clones and changes in V(D)J gene expression;TCR peptide chain pairing information;transcriptional level;Assessment of pulmonary damage;Activation pathways and the expression of key transcription factors in diverse cellular subpopulations; | — |
Countries
China
Contacts
Public ContactShuihua Lu
The Third People's Hospital of Shenzhen
Outcome results
None listed